국제특허분쟁연구회

Thursday, January 7, 2010, 2:38pm EST AstraZeneca, Teva settle patent litigation over Nexium and Prilosec Philadelphia Business Journal - by John George Staff Writer Pharmaceutical Industries Ltd. agreed Thursday to settle patent litigation regarding Teva’s U.S. generic versions of AstraZeneca’s Prilosec and Nexium products for heartburn and acid reflux. Through the Prilosec agreement, Teva (NASDAQ:TEVA) will obtain a release for all past sales of its generic omeprazole, will continue to market its product in the United States, and will make a one-time payment to AstraZeneca (NYSE:AZN) for past sales of the generic. The amount of the payment was not disclosed. As part of the Nexium agreement, AstraZeneca has granted Teva a license, subject to regulatory approval, to enter the U.S. market with its generic delayed-release capsules on May 27, 2014, or earlier in certain circumstances. Teva, as part of the agreement, conceded that all patents at issue in Teva’s U.S. Nexium patent litigations are valid and enforceable. Teva has also conceded that six Nexium patents would be infringed by the manufacture or sale of Teva’s generic Nexium product. Additional details were not disclosed. Teva of Jerusalem, Israel, has its U.S. headquarters in North Wales, Pa. AstraZeneca, based in London, has its U.S. headquarters in Wilmington, Del.